A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Komninos, 2004, Tumors metastatic to the pituitary gland: case report and literature review, J Clin Endocrinol Metab., 89, 574, 10.1210/jc.2003-030395
Marsh, 2010, Intracranial metastatic disease rarely involves the pituitary: retrospective analysis of 935 metastases in 155 patients and review of the literature, Pituitary., 13, 260, 10.1007/s11102-010-0229-4
Shimon, 2020, Metastatic spread to the pituitary, Neuroendocrinology.
Nelson, 1987, Metastatic tumor of the pituitary gland, Neurosurgery., 21, 941, 10.1227/00006123-198712000-00030
Javanbakht, 2018, Pituitary metastasis: a rare condition, Endocr Connect., 7, 1049, 10.1530/EC-18-0338
MacKie, 2009, Epidemiology of invasive cutaneous melanoma, Ann Oncol., 20, vi1, 10.1093/annonc/mdp252
Garbe, 2009, Melanoma epidemiology and trends, Clin Dermatol., 27, 3, 10.1016/j.clindermatol.2008.09.001
Matthews, 2017, Epidemiology of melanoma, Cutaneous Melanoma, Etiology and Therapy, 3, 10.15586/codon.cutaneousmelanoma.2017.ch1
Rastrelli, 2014, Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification, In Vivo., 28, 1005
Tas, 2019, Early and late relapses of cutaneous melanoma patients, Postgrad Med., 131, 207, 10.1080/00325481.2019.1569354
Leung, 2003, Metastatic melanoma of the pituitary gland, Case report. J Neurosurg., 99, 913, 10.3171/jns.2003.99.5.0913
McCutcheon, 2007, Metastatic melanoma to the pituitary gland, Can J Neurol Sci., 34, 322, 10.1017/S0317167100006752
Masui, 2013, Pituitary apoplexy caused by hemorrhage from pituitary metastatic melanoma: case report, Neurol Med Chir (Tokyo)., 53, 695, 10.2176/nmc.cr2012-0068
Guzel, 2009, Multiple intracranial melanoma metastases: case report and review of the literature, J Neurooncol., 93, 413, 10.1007/s11060-008-9785-0
Yang, 2017, Progressive visual disturbance and enlarging prolactinoma caused by melanoma metastasis: a case report and literature review, Medicine., 96, e6483, 10.1097/MD.0000000000006483
Jung, 2007, A man in his mid-70s with a sellar mass, Brain Pathol., 17, 115–6, 10.1111/j.1750-3639.2007.00044_1.x
Louveau, 2015, Structural and functional features of central nervous system lymphatic vessels, Nature., 523, 337, 10.1038/nature14432
Habu, 2015, Pituitary metastases: current practice in Japan, J Neurosurg., 123, 998, 10.3171/2014.12.JNS14870
He, 2015, Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis, Pituitary., 18, 159, 10.1007/s11102-014-0552-2
Patel, 2019, Extended survival after surgical resection for pituitary metastases: clinical features, management, and outcomes of metastatic disease to the sella, Oncologist., 25, e789, 10.1634/theoncologist.2019-0520
Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med., 373, 23, 10.1056/NEJMoa1504030
Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med., 372, 2521, 10.1056/NEJMoa1503093
Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet., 384, 1109, 10.1016/S0140-6736(14)60958-2
Topalian, 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol., 32, 1020, 10.1200/JCO.2013.53.0105
Colombino, 2012, BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma, J Clin Oncol., 30, 2522, 10.1200/JCO.2011.41.2452
Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet., 380, 358, 10.1016/S0140-6736(12)60868-X
Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med., 364, 2507, 10.1056/NEJMoa1103782
Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902
Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med., 372, 30, 10.1056/NEJMoa1412690
Greco, 2019, Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review, Cancers., 11, 1950, 10.3390/cancers11121950
Dummer, 2015, Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol., 26, v126, 10.1093/annonc/mdv297
Network, 2020, NCCN clinical practice guideline in oncology, cutaneous melanoma. Version 2.2020
Hamid, 2019, Efficacy, safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma, Cancers., 11, 1642, 10.3390/cancers11111642
Long, 2018, Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib, J Clin Oncol., 36, 667, 10.1200/JCO.2017.74.1025
Brugnara, 2018, Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation, Drugs Context., 7, 212515, 10.7573/dic.212515
Vlotides, 2007, Pituitary tumor-transforming gene: physiology and implications for tumorigenesis, Endocr Rev., 28, 165, 10.1210/er.2006-0042
Caporali, 2017, Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib, Oncotarget., 8, 113472, 10.18632/oncotarget.23052